Ionis Pharmaceuticals, Inc. (IONS) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Carlsbad, CA, アメリカ. 現CEOは Brett Monia.
IONS を有する IPO日 1991-05-17, 1,069 名の正社員, に上場 NASDAQ Global Select, 時価総額 $12.68B.
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, specializing in the discovery and development of RNA-targeted therapeutics. The company markets approved treatments including SPINRAZA for spinal muscular atrophy, TEGSEDI for hereditary transthyretin-mediated amyloidosis, and WAYLIVRA for familial lipid disorders, while maintaining a robust pipeline of Phase 3 candidates targeting rare genetic diseases, cardiovascular conditions, and neurological disorders. Through strategic collaborations with major pharmaceutical partners including Biogen, AstraZeneca, Bayer, GlaxoSmithKline, Novartis, and Roche, Ionis is advancing its platform across metabolic diseases, infectious diseases, renal diseases, and oncology.
